

Summary of Business and Competence

World leader on Multi-modal measurements

Corpus expertise in identifying important areas in Medical Diagnostics using spectroscopic- and advanced data analysis studies have resulted in developing the platform "DermaProbe™", where complex data analysis from multivariate- and hyperspectral spectroscopic measurements have formed our proprietary and patented Corpus AI solution. The company's customers are providers of Med Tech equipment, world-wide.

Clinical acceptance

DermaProbe™ has been tested and clinically evaluated since 2016 at University Hospitals as well as in out-patient centers in Sweden. A study normally takes a few minutes making the device well suited for screening purposes. The science behind DermaProbe has been documented by numerous clinical publications and academic thesis.



DermaProbe Market

There is a profitable market for DermaProbe. The global Dermatology Devices Market, that includes both diagnostic and treatment devices, was valued in 2016 to \$8.22 Billion, and it is expected to reach \$14.17 Billion by 2021, growing at a CAGR of 11.50%. Skin Cancer and Diabetes Induced Neuropathy are segments in critical Health Care that is growing faster than others, due to increased detected cases of melanoma caused by exposure to sun and UV rays and aging of population .

- Most suitable for preventive • Health Care Direct readout on a screen
- Sensitive and reproducible results • Easy-to-use for health care personnel

OEM partners

"Corpus expertise is in identifying and finding solutions of important areas in Medical Diagnostics", says CEO, Ms. Gunilla Nordström. Emphasis has been placed on developing the platform DermaProbe for spectroscopic studies and advanced data analysis, where complex data analysis from multivariate- and hyperspectral spectroscopic measurements have formed our development of proprietary AI solutions. A strength for the company is that the major shareholders also have been members of the Board since the company was founded.



Innovative product concept

Corpus are active in the development of revolutionary analyzers for the dermatology market. With supporting AI applications and software-interfaces, a unique concept is formed that replace or assist the conventional dermatology readings by trained dermatologists. The products can be combined and configured with a high degree of flexibility, making it possible to effectively accommodate the needs of several other skin-related problems. Corpus primary focus is offering product solutions for the healthcare market.



Skin cancer

To promote economic savings in healthcare and to save precious lives of Malignant Melanoma (MM) patients, the society is in need of new, fast and reliable diagnostic methods for detecting early stages of MM. Corpus have recognized this market opportunity and have developed DermaProbe, a revolutionary melanoma diagnosis device easy to use by nurses and General Practitioners (GPs) without any specific training. It is a safe device and >95% accurate when distinguishing between benign and tumor skin lesions, highest rating on the market.

Diabetes induced neuropathy

Since the development of diabetic neuropathy is length-dependent, measurements and diagnosis have to be performed on a regular basis to follow changes in the extremities, not only primarily on the foot. The DermaProbe system is built for very fast diagnosis and has a very short introduction-period for the health care staff. Some of the features of DermaProbe are:

- Suitable for preventive Health Care
- Sensitive and reproducible
- Easy-to-interpret the clinical test reports
- Easy data export to excel and other datasheets